Analyst Profile

Followed by 571 followers
.
Ed Arce

Ed Arce

H.C. Wainwright
Wall Street Analyst
#3,012 out of 8,141 Wall Street Analysts
#6,873 out of 24,284 experts

Success Rate

35%
139 out of 392 transactions made a profit

Average Return

+1.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Ed Arce's trades since 2012 and holding each position for 1 Year would result in 35.46% of your transactions generating a profit, with an average return of 1.9% per rating.

Stock Rating Distribution

1KRatings
82.26% Buy
17.49% Hold
0.24% Sell
Distribution of Ed Arce's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Arcturus Therapeutics
(ARCT)
Rating:Buy
Date:Dec 13, 2019 - Dec 13, 2020
Return:+800.00%
The most profitable rating made by Ed Arce

Ed Arce's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
RDEA
Ardea Biosciences
Apr 23, 2012
Hold
Assigned
1Ratings
0.00%
Affymax
Mar 19, 2013
Sell
Downgraded
$0.50
(7964.52% Upside)
2Ratings
0.00%
NPSP
NPS Pharma
May 17, 2013
Buy
Reiterated
1Ratings
0.00%
DRTX
Durata
Oct 15, 2014
Hold
Downgraded
7Ratings
0.00%
Xoma
Nov 14, 2014
Buy
Reiterated
$9.00
(-57.22% Downside)
3Ratings
0.00%
Acura Pharmaceuticals
Jan 09, 2015
Buy
Reiterated
$5.00
(9900.00% Upside)
8Ratings
0.00%
BioCryst
Jan 26, 2015
Buy
Reiterated
$20.00
(58.23% Upside)
12Ratings
0.00%
Neptune Wellness Solutions
Jan 30, 2015
Buy
Reiterated
$5.00
(557.89% Upside)
1Ratings
0.00%
SCMP
Sucampo Pharmaceuticals
Aug 24, 2015
Buy
Initiated
12Ratings
0.00%
RLYP
Relypsa Inc
Jul 22, 2016
Hold
Downgraded
6Ratings
0.00%
List of latest recommendations made by Ed Arce. Click to expand and see Ed Arce's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >